Sagimet Biosciences (NASDAQ:SGMT) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Sagimet Biosciences (NASDAQ:SGMT) from a hold rating to a sell rating in a research report report published on Saturday morning.

Several other analysts have also commented on the company. Citizens Jmp raised their target price on Sagimet Biosciences from $12.00 to $29.00 and gave the stock a “market outperform” rating in a report on Friday. Citigroup restated a “market outperform” rating on shares of Sagimet Biosciences in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sagimet Biosciences in a research note on Friday, July 17th. Guggenheim reduced their price target on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Finally, Canaccord Genuity Group increased their price target on Sagimet Biosciences from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday. Seven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Sagimet Biosciences presently has an average rating of “Moderate Buy” and an average target price of $29.17.

Sagimet Biosciences Trading Up 13.7%

Shares of NASDAQ SGMT opened at $10.55 on Friday. Sagimet Biosciences has a 12 month low of $4.50 and a 12 month high of $10.60. The company has a 50 day simple moving average of $7.51 and a two-hundred day simple moving average of $6.57. The stock has a market cap of $343.72 million, a price-to-earnings ratio of -8.24 and a beta of 3.37.

Sagimet Biosciences (NASDAQ:SGMT) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Analysts forecast that Sagimet Biosciences will post -1.2 EPS for the current year.

Insider Buying and Selling

In related news, CEO David Happel sold 64,051 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $7.76, for a total transaction of $497,035.76. Following the completion of the transaction, the chief executive officer owned 741,570 shares in the company, valued at $5,754,583.20. This represents a 7.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $9.95, for a total transaction of $201,049.70. Following the completion of the transaction, the director directly owned 62,161 shares in the company, valued at $618,501.95. This represents a 24.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 113,646 shares of company stock worth $920,491 in the last 90 days. Insiders own 11.50% of the company’s stock.

Institutional Trading of Sagimet Biosciences

A number of institutional investors have recently made changes to their positions in SGMT. NewEdge Advisors LLC purchased a new position in shares of Sagimet Biosciences in the first quarter worth about $105,000. Geode Capital Management LLC boosted its holdings in shares of Sagimet Biosciences by 0.6% during the 2nd quarter. Geode Capital Management LLC now owns 265,324 shares of the company’s stock worth $2,023,000 after purchasing an additional 1,600 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Sagimet Biosciences by 8.9% during the 2nd quarter. American Century Companies Inc. now owns 42,285 shares of the company’s stock worth $322,000 after purchasing an additional 3,454 shares during the last quarter. XTX Topco Ltd grew its position in shares of Sagimet Biosciences by 137.0% in the second quarter. XTX Topco Ltd now owns 25,624 shares of the company’s stock valued at $195,000 after purchasing an additional 14,813 shares in the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of Sagimet Biosciences in the second quarter valued at approximately $1,130,000. 87.86% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: FDA clears Phase 3 acne study: The FDA accepted Sagimet’s Investigational New Drug application and issued a “Study May Proceed” letter for a U.S. Phase 3 trial of oral, once-daily denifanstat in moderate to severe acne. The trial is expected to begin in the second half of 2026 and enroll approximately 800 patients, including about 450 adolescents. This advances the company’s lead program into a late-stage study and could materially improve its commercial prospects if efficacy and safety are confirmed. FDA Study May Proceed letter and IND clearance
• Positive Sentiment: Citizens JMP raises price target: Citizens JMP increased its target for Sagimet from $12 to $29 and maintained a “Market Outperform” rating. The higher target reflects stronger expectations for denifanstat’s development following the FDA clearance. Citizens JMP price target update
• Positive Sentiment: Additional analyst support: Canaccord Genuity also issued a bullish outlook for SGMT, adding to generally positive Wall Street sentiment around the company’s pipeline and potential future appreciation. Canaccord Genuity Sagimet forecast
• Negative Sentiment: Continued operating losses: Sagimet reported a quarterly loss of $0.26 per share, slightly worse than the $0.25 analyst consensus, while HC Wainwright lowered its fourth-quarter loss estimate to $0.32 per share. The company remains dependent on clinical progress and likely future financing.
• Negative Sentiment: Insider selling: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. Although the sale may be routine, it could temper investor sentiment following the recent rally. George Kemble insider sale

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.